✦ LIBER ✦

Lisuride treatment of Restless Legs Syndrome: first studies with monotherapy in de novo patients and in combination with levodopa in advanced disease

✍ Scribed by H. Beneš; A. Deissler; A. Rodenbeck; A. Engfer; R. Kohnen

Publisher: Springer
Year: 2006
Tongue: English
Weight: 73 KB
Volume: 113
Category: Article
ISSN: 1435-1463
DOI: 10.1007/s00702-005-0386-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cabergoline compared to levodopa in the

Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi-center, randomized, active controlled trial

✍ Claudia Trenkwalder; Heike Benes; Ludger Grote; Svenja Happe; Birgit Högl; Johan 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 1 views

## Abstract We report the first large‐scale double‐blind, randomly assigned study to compare two active dopaminergic therapies for Restless Legs Syndrome (RLS), the dopamine agonist cabergoline (CAB) and levodopa/benserazide (levodopa). Patients with idiopathic RLS were treated with fixed daily dos

Acute double-blind, placebo-controlled s

Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome

✍ M. Saletu; P. Anderer; B. Högl; G. Saletu-Zyhlarz; A. Kunz; W. Poewe; B. Saletu 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 153 KB

The combination of gemcitabine and carbo

The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma : A Phase II study of the Hellenic Cooperative Oncology Group

✍ Aristotle Bamias; Lia A. Moulopoulos; Aggelos Koutras; Gerassimos Aravantinos; G 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

## Abstract ## BACKGROUND The toxicity of platinum‐based combinations represents a common problem for patients with advanced urothelial carcinoma. The authors previously reported encouraging efficacy for the combination of carboplatin and gemcitabine in patients considered to be unfit for cisplati